Family First Health

Pharma Tech

Astellas Pharma Inc. | September 30, 2022

Astellas Pharma Inc. announced the European Medicines Agency has accepted for regulatory review the company's marketing authorization application for fezolinetant, an investigational oral, nonhormonal compound seeking approval for the treatment of moderate to severe vasomotor symptoms associated with menopause. VMS, characterized by hot flashes and/or night sweats, are common symptoms of menopause.1,2 "More than half of women 40 to 64 years of age ex...

Pharmacy Market

Eagle Pharmaceuticals, Inc. | March 29, 2022

Eagle Pharmaceuticals, Inc. reported that it had achieved an agreement with Acacia Pharma Group plc on the parameters of a plan of arrangement under Part 26 of the United Kingdom's Companies Act 2006. Acacia Pharma's current issued and to be issued, share capital is valued at approximately €94,700,000, or the equivalent of €0.90 per share, under the terms of the proposed transaction. Each Acacia Pharma shareholder would get €0.68 in cash and 0.0049 shares of...

Pharma Tech

Medable Inc. | February 03, 2022

Medable Inc., the leading software provider for patient-centered clinical trials, tannounced that it has acquired LEO Innovation Lab’s Omhu A/S, a Denmark-based digital health tech company. Omhu was launched in 2020 to develop new ways of supporting patients and doctors when diagnosing, managing, and treating skin conditions. As part of the agreement with LEO Pharma A/S (owner of LEO Innovation Lab), Medable will take over the Omhu mobile applications and a talented team of 38 people with ...

Pharmafile: Home | February 11, 2020

The Ebola drug Remdesivir, made by Gilead Sciences, was given to an American who is 35 years old. The doctors reported that on 26 January his condition seemed to improve within a day, and by 30 January it had resolved most of the symptoms except a cough. However, Gilead feel this is not conclusive proof that it's an effective treatment. Ryan McKeel, a spokesperson for the company, said: “We do not have an appropriately robust understanding of the effect of this drug to warrant broad us...